Clinical Data

U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer | Business Wire | 4/4/2019

… the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and …

U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer | Business & Finance | heraldchronicle.com | Business Wire | 4/4/2019

… the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and …

Follow Clinical Data:    

Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript) | Seeking Alpha | 4/6/2019

Sangamo Therapeutics, Inc. (NASDAQ: SGMO ) Clinical Development Update Conference Call April 2, 2019 8: McDavid Stilwell - Vice President, Corporate Communications & Investor Relations Sandy Macrae - Chief Executive Officer Stephane Boissel - Executive Vice President, Corporate Strategy Adrian Woolfson - Executive Vice President & Head of Research and Development Ed Conner - Chief Medical Officer Maurice Raycroft - Jefferies Jim Birchenough - Wells Fargo Gena Wang - Barclays Boran Wang - Guggenheim Securities Qian Wang - Bank of America Merrill Lynch …

Specific contribution of mannose-binding lectin murine isoforms to brain ischemia/reperfusion injury | Nature | 4/9/2019

… brain ischemia, the functional similarities between the murine MBL isoforms and human MBL are underinvestigated. Although we suggest that MBL-A (less similar to human MBL) is the main contributor to brain ischemic injury, clinical data show that stroke patients with MBL deficiency develop less-severe injury than those without, 8 mirroring the observations in the mouse knockout model. Human MBL is therefore a key contributor to postischemic damage. Accordingly …

Medidata Launches Acorn AI™ and Appoints Dr. Rama Kondru as CIO | 4/11/2019

… D to commercialization. Leveraging the companys AI capabilities and expertise, customers and partners can now unlock the power of data to conquer the most complex diseases. Fueled by one of the largest regulatory-grade clinical data repositories in the world and built upon Medidata’s cutting-edge platform, Acorn AI immediately becomes one of the leading AI companies dedicated to life sciences. The new business is backed by: Medidatas cumulative R …

Medidata Launches Acorn AI™ and Appoints Dr. Rama Kondru as CIO: Medical Press Releases | 4/11/2019

… enabling customers to improve outcomes for patients and to accelerate growth The Acorn AI team is led by industry veterans who are shaping the future of life sciences Powered by Medidata’s standardised and structured clinical data repository, one of the largest in the world, Acorn AI immediately becomes a leading AI company dedicated to life sciences Industry visionary, Rama Kondru, Ph.D., is appointed CIO of Medidata and CTO of Acorn …

Medidata Solutions, Inc. (MDSO) CEO Tarek Sherif on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/1/2019

… powers over 1,200 of the world’s most innovative life sciences companies development, and we hold their most valuable IP. Nearly a decade ago, we began amassing what has become the industry’s largest structured standardized clinical data repository. It’s unique in its scale, global footprint and breadth. Simply put, it’s one of a kind in the world and it has tremendous scientific and ethical value. Acorn is in part designed to …

Diameter Health Announces $9.6 Million in Series A-1 Funding Round | Business Wire | 4/9/2019

Diameter Health Announces $9.6 Million in Series A-1 Funding Round 2 hrs ago Save FARMINGTON, Conn.–(BUSINESS WIRE)–Apr 9, 2019– Diameter Health , a market leader in clinical data integration, today announced a $9.6 million Series A-1 funding round. The investment is led by new investor Optum Ventures , the independent venture fund of Optum. Optum Ventures joins existing Diameter Health investors Activate Venture Partners , Connecticut Innovations , Excelerate Health …

Amgen Inc. (AMGN) CEO Bob Bradway on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/1/2019

… provide an update on the dose escalation trial of our first generation BCMA BiTE molecule, AMG 420. We are now enrolling patients in a dose expansion study. We also expect some of the first clinical data from our new generation BiTE platform by the end of the year with AMG701 and extended half life BCMA BiTE molecule. Our enthusiasm is high for our BCMA BiTE molecules as well as our …

Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™ | Business Wire | 4/12/2019

PASADENA, Calif.- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), demonstrating that sustained reduction of mutant Z-AAT protein by RNA interference (RNAi) substantially reversed the alpha-1 antitrypsin deficiency (AATD) disease phenotype in the PiZ mouse model. Arrowhead has completed a Phase 1 clinical trial of ARO …

ResMed, Inc. (RMD) CEO Michael Farrell on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/3/2019

… When you couple that with the difficulty of getting the right care at the right time, delivering that health care in low cost setting and even further changes in challenges with interoperability, documentation, and clinical data availability. It’s a global healthcare system that is in the costs. When solutions in a microeconomic side, with ResMed’s global leadership in digital health for sleep apnea or COPD and for outside of the …

Guardant Health: Bright Future For Liquid Biopsy Leader, But Valuation Is Rich - Guardant Health, Inc. (NASDAQ:GH) | Seeking Alpha | 5/2/2019

… of immuno-oncology as it can call out MSI, tumor mutational burden (TMB) and includes over 500 genes that comprise targets for most therapeutic options today. Another significant differentiator is the sheer amount of clinical data supporting the company’s technology, as management recognized early on the importance of investing in lengthy (and costly) studies. Guardant360 has already been the subject of over 40 clinical studies with over 100 peer-reviewed …

Mallinckrodt: One-Year Review - Mallinckrodt plc (NYSE:MNK) | Seeking Alpha | 4/8/2019

… launch a competing product in 2H 2020. Management seems confident of meeting the timeline and does not see any roadblocks to approval. However, getting payer coverage will be challenging as payers look out for clinical data which is lacking for ANIP’s product. This is a challenge that Acthar is facing now, which has prompted the multiple Phase 4 studies (Refer to Figure 1 for a timeline of trial results). I …

SacValley MedShare Accelerates Interoperability Scale with the Zen Healthcare IT Gemini Integration Platform | PRWeb | 4/29/2019

SacValley MedShare Accelerates Interoperability Scale with the Zen Healthcare IT Gemini Integration Platform Share Article Improving Clinical Data Exchange, Patient Safety, and Information Access. We (SVMS) are able to better leverage our full technology stack so our providers can more effectively share information to improve patient care. COSTA MESA, Calif. (PRWEB) April 29, 2019 Zen Healthcare IT (“Zen”), a leader in healthcare data interoperability technology and services, has been selected …

Description of the BRIGHTLIGHT cohort: the evaluation of teenage and young adult cancer services in England | BMJ | 4/20/2019

… with place of care, experience and outcome. This is made possible through the use of linked data from multiple sources, so unlike other cohorts that rely solely on patient-reported outcomes 34 47 or clinical data , 32 a more comprehensive evaluation can be derived. Using national mandatory NHS datasets, we have been able to calculate a more robust measure of time spent in specialist TYA care. Other data sources, such …

Cortexyme Files For U.S. IPO - Cortexyme (Pending:CRTX) | Seeking Alpha | 4/17/2019

… SGI] that effectively crosses the blood-brain barrier. Gingipains are secreted by Porphyromonas gingivalis, an intracellular bacteria that is present in 80 to 90% of all AD patients. Management states that according to new clinical data , gingipains have been found to cause Alzheimer’s pathology in animal models. Moreover, AD pathology is thought to mimic that of an infection - for example, the presence of amyloid beta, a peptide that was recently …

Precision Biosciences, Recent IPO: Unique ARCUS Gene Editing And Allogeneic CAR-T Platform - Precision BioSciences, Inc. (NASDAQ:DTIL) | Seeking Alpha | 4/22/2019

… editing platform. Risks like off-target mutations which may even result in serious side effects like cancer may be seen if the gene editing is not specific only to the targeted organ. If the clinical data is not satisfactory or side effects are seen, it is possible that the current partnerships with big pharma like Gilead, Shire, etc. may be broken which may put considerable financial burden on Precision Bio …

Independent Practices Form Pediatric-Focused, Clinically Integrated Network on Long Island | 4/9/2019

… A group of eight independent pediatric practices on Long Island, New York have joined forces to form a clinically integrated network, the Independent Pediatric Collaborative of Long Island, LLC (IPCLI) , in order to share clinical data , reduce costs of care and collaborate in order to build on and improve pediatric care delivery on Long Island. Empowering member practices with the tools they need to reduce operational costs, enhance a practice’s …

Repro Med Systems, Inc. (REPR) CEO Don Pettigrew on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/4/2019

… Brian will be a great help to RMS Medical as we pursue broader and deeper relationships with clinicians and potential pharmaceutical company partners to expand our market opportunity as well as provide an improved clinical data platform. These are key components of our strategic plan. At our Annual Meeting of Shareholders held on April 23, Kathy Frommer was elected to our board, a longtime shareholder of RMS Medical. Kathy has …

Susmed: Demonstration of Clinical Data Managing System Using Blockchain Technology | Business Wire | 4/22/2019

… and development of smartphone applications as software medical devices for treatment of diseases such as insomnia. It today announced that “Regulatory Sandbox System” 2 , pilot projects led by Japanese government, on the “Demonstration of Clinical Data Monitoring System Using Blockchain Technology”, hereinafter referred to as “the pilot project”, has been certified by the Ministry of Health, Labor, and Welfare and the Minister of Economy, Trade and Industry. Susmed is developing …

VISITOR Clinical Study Demonstrates Feasibility and Utility of Transparency Life Sciences’ New Virtual Trials Platform | PR Newswire | 4/16/2019

… today announced the successful completion of its VISITOR (VIrtual, SIteless, Technology Open Research) clinical trial. VISITOR was designed to assess the feasibility and ease, along with the quality and integrity, of collecting research-grade clinical data directly from subjects in their homes or offices using the Transparency Virtual Trials TM (TVT) digital study hub. The study demonstrated that participants were quickly able to adapt to using telemedicine devices to capture …

GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial | Markets Insider | Business Insider | 4/8/2019

TAMPA, Florida , April 8, 2019 /CNW/ –GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology biotechnology company focused on innovative treatments based on the Company’s proprietary NK-engager (TriKE) platform and Multi-Target Bispecific Drug Conjugate (MTBDC) platform, announced today it has received authorization from the University of Minnesota’s Institutional Review Board (IRB) and Cancer Protocol Review Committee (CPRC) that it can proceed with its planned TriKE Phase 1 clinical …

Recondo Technology Accelerating Momentum in Healthcare Revenue Cycle | Markets Insider | Business Insider | 4/9/2019

… less than half of that time. Recondo will further whittle processing time down to a mere 1 to 3 minutes by pairing its patented ReconBotâ RPA capability with natural language processing models to extract clinical data from the provider’s EMR. This data, which previously had to be inputted manually, will now be auto-populated into the prior authorization request and auto-submitted to the payer. “The potential this technology and …

4medica Perfect Order for Perfect Payment Solution Launched at Executive War College 2019 | PRWeb | 4/30/2019

… administrators can take action proactively to resolve earlier in the process rather than reactively on the back end.” About 4medica 4medica provides the industry’s leading SaaS (software-as-a-service) Big Data Management and Clinical Data Exchange platforms to help healthcare organizations of diverse types create a seamless view of the patient care experience and further drive better health outcomes. The 4medica Big Data MPI™, 4medica Big Data CDR™, 4medica …

Get Real Health Provides HealthVault Users with a New Home | PRWeb | 4/5/2019

… exciting tools to use their data in meaningful ways, improve habits, and overall wellness.” About Get Real Health Get Real Health combines a world of new information from patients, devices and apps with existing clinical data to help individuals and healthcare professionals engage and empower each other. By giving providers and patients the information and tools they need to work together, we help our customers meet their ever-changing patient …

Food and Drug Administration

Users Marvel at Medical Cannabis’ Myriad of Applications | PR Newswire | 8/21/2020

… market share, and progress is slowly being made in removing the stigmas associated with such products. For instance, the U.S. Food and Drug Administration approved the first marijuana-derived drug to treat epilepsy, Epidiolex. The … Clean Beauty and Flavors & Fragrances markets, announced back in March clinical data showcasing the superiority of its natural sugarcane squalane (marketed and sold as Neossance Squalane) as a carrier of CBD versus other oils. In …

COVID-19

First Edition: Aug. 21, 2020 - Kaiser Health News | 8/21/2020

… Says COVID Is A Lower Risk For School-Aged Kids Than Flu Even as his state is a hotbed for COVID-19, Florida Gov. Ron DeSantis has been pushing schools to reopen so parents have … in JAMA, described studying self-collected and mailed samples and clinical data gathered through phone interviews from Mar 27 to May 6. The mothers’ babies ranged in age from newborn to 19 months, and each …

American Urological Association

NeoTract Designates Dr. Thomas Facelle as UroLift® Center of Excellence | PRWeb | 8/20/2020

… associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate. Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral … the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and …

AHIP

What the Interoperability Rule Will Mean for Payers in 2021 | HealthPayer Intelligence | 8/20/2020

… can be aware of what to expect regarding how this rule will change their processes, as outlined in a recent AHIP brief . “The final rules include policy changes designed to support the Administration’s MyHealthEData initiative … share data on provider payer amounts, patient cost-sharing information, clinical data points, and more. Importantly, payers cannot require members to use payer apps. Web-based technology will be in competition with third-party vendors …

Urology

NeoTract Designates Dr. Thomas Facelle as UroLift® Center of Excellence | PRWeb | 8/20/2020

… Calif. NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Thomas Facelle, M.D., Colorado Urology in Golden, CO, has been designated … the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and …

CDC

Validation of automated sepsis surveillance based on the Sepsis-3 clinical criteria against physician record review in a general hospital population: observational study using electronic health records data | BMJ | 8/19/2020

… such surveillance systems require standardised case-definitions free from subjective interpretations and appropriate denominator data. 6 Surveillance systems based on clinical data are preferred to administrative data, as these are more objective, reproducible and stable … evaluated. In 2018, the Center of Disease Control and Prevention (CDC) presented an additional sepsis definition called Adult Sepsis Event (ASE) aimed specifically for surveillance purposes. 14 The ASE differs from the Sepsis-3 clinical …

National Cancer Institute

CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11 | PR Newswire | 8/18/2020

… the study at Massachusetts General Hospital/ Harvard Medical School and Hackensack University Medical Center are joining existing sites at the National Cancer Institute at the National Institutes of Health and Washington University in St. Louis … abstract . Following the expansion of the Phase I trial, preliminary clinical data for the existing no-preconditioning MCY-M11 trial are anticipated in H2 2020. “We are very pleased with the progress of this first …

UC Davis

COVID Data Failures Create Pressure for Public Health System Overhaul | Physicians Weekly | 8/18/2020

UC Davis Health, along with nearly 30 other provider organizations around the country, recently launched a collaborative effort to speed and improve the sharing of clinical data on individual COVID cases with public health departments. But even that platform, which contains information about patients’ diagnoses and response to treatments, doesn’t yet include data on the availability of hospital beds, intensive care units or supplies needed for a seamless pandemic response …

Hematology

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 8/17/2020

… in boys with cerebral adrenoleukodystrophy (ALD-102 and ALD-104) Presenting Author: Dr. Jörn-Sven Kühl, Department of Pediatric Oncology, Hematology and Hemostaseology, Center for Women’s and Children’s Medicine, University Hospital Leipzig Poster Session & Number … with the U.S. Food and Drug Administration (FDA) that the clinical data package required to support a Biologics Licensing Application (BLA) submission for LentiGlobin for SCD will be based on data from a portion of …

Medical Imaging

NIH Leverages AI in Medical Imaging Center for COVID-19 Treatment | HIT Infrastructure | 8/14/2020

Networking News NIH Leverages AI in Medical Imaging Center for COVID-19 Treatment The medical imaging center will use AI to enable researchers to evaluate tissue and develop predicted coronavirus imaging signatures that can be … rapid and flexible collection and analysis of imaging and associated clinical data, NIH said. Participating organizations will provide expertise within medical imaging, imaging data quality, security, access, and sustainability. “This major initiative responds to the …

AMA

AMA, SNOMED International Join Forces to Enhance Patient Care | EHR Intelligence | 8/14/2020

Intertwining AMA CPT codes and SNOMED CT aims to improve patient care by streamlining resource utilization insights. Source: Thinkstock Photos By August 14, 2020 - The American Medical Association (AMA) and SNOMED International have announced an … enables a consistent way of indexing, storing, retrieving, and aggregating clinical data across specialties and sites of care, according to the organization. Dig Deeper How Health Data Standards Support Healthcare Interoperability This project aims to …

NIH

NIH Leverages AI in Medical Imaging Center for COVID-19 Treatment | HIT Infrastructure | 8/14/2020

Networking News NIH Leverages AI in Medical Imaging Center for COVID-19 Treatment The medical imaging center will use AI to enable researchers to evaluate tissue and develop predicted coronavirus imaging signatures that can be … rapid and flexible collection and analysis of imaging and associated clinical data, NIH said. Participating organizations will provide expertise within medical imaging, imaging data quality, security, access, and sustainability. “This major initiative responds to the …

Biotech

Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results | PR Newswire | 8/14/2020

Biotech Inc. on filovirus vaccines (protecting against viruses such as Ebola and Marburg) and the development of vaccines to potentially combat coronaviruses, including SARS-CoV-2, the cause of COVID-19. We recently announced publication of positive pre-clinical data from immunogenicity studies with CiVax™ (heat stable COVID-19 vaccine candidate), demonstrating immunity of both broad-spectrum antibody and cell-mediated, rapid onset immunity is possible using the CoVaccine HT …

American Medical Association

AMA, SNOMED International Join Forces to Enhance Patient Care | EHR Intelligence | 8/14/2020

American Medical Association (AMA) and SNOMED International have announced an initiative to improve resource utilization throughout healthcare and provide better health outcomes. The initiative is a demonstration of how AMA’s Current Procedural Terminology (CPT) and SNOMED CT can work together to achieve that initial goal. SNOMED CT terminology provides a universal language that enables a consistent way of indexing, storing, retrieving, and aggregating clinical data across specialties and sites of …

AACR

Cellular Biomedicine Group (CBMG) Reports Q2, H1 2020 Financial Results and Business Highlights | PR Newswire | 8/12/2020

… AlloJoin TM knee osteoarthritis (KOA) Phase II trial. We plan to submit and present the C-CAR088 and C-CAR039 clinical data at a major conference later this year. We are happy to report that … a poster presentation at the American Association for Cancer Research (AACR) annual meeting: “Selecting Clinical Lead of TCRs Targeting Alpha-Fetoprotein-Positive Liver Cancer on Balance of Risk and Benefit” On July 13, 2020 , the …

American Association for Cancer Research

Cellular Biomedicine Group (CBMG) Reports Q2, H1 2020 Financial Results and Business Highlights | PR Newswire | 8/12/2020

… AlloJoin TM knee osteoarthritis (KOA) Phase II trial. We plan to submit and present the C-CAR088 and C-CAR039 clinical data at a major conference later this year. We are happy to report that … the safety and efficacy Conducted a poster presentation at the American Association for Cancer Research (AACR) annual meeting: “Selecting Clinical Lead of TCRs Targeting Alpha-Fetoprotein-Positive Liver Cancer on Balance of Risk and Benefit …

American Society of Clinical Oncology

Cardiff Oncology Announces Second Quarter 2020 Results and Highlights | PR Newswire | 8/11/2020

… milestones that have driven our sustained growth,” said Dr. Mark Erlander , chief executive officer of Cardiff Oncology. “We announced compelling clinical data demonstrating the safety and efficacy of ovansertib in combination with standard-of-care … onvansertib in patients with KRAS-mutated mCRC at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. Newly announced data from a Phase 1b /2 clinical trial demonstrate the safety and efficacy of onvansertib …

AWS Healthcare

Critical Need for Actionable COVID-19 Healthcare Data Fuels Cloudticity’s Strong Market Momentum in 2020 | PRWeb | 8/11/2020

clinical data in real time to see emerging trends/changes, intelligently manage their ventilator inventories and ICU beds, and uncover deeper correlations with machine learning—such as comorbidities, demographics, social determinants, etc.—that often influence COVID-19 outcomes.” Cloudticity has built some of the largest healthcare systems on Amazon Web Services (AWS), including the first patient portal, the first health information exchange (HIE), and the first FISMA high deployment on …

HITRUST CSF

AO Foundation, OBERD launch AO Global Data to transform patient-reported outcomes collection | PR Newswire | 8/11/2020

… technique advancements. Remote Monitoring : Track your patient over time with alerts for potential adverse events. Data Security: This platform is HITRUST CSF® certified meeting the most stringent levels of security. The HITRUST CSF leverages nationally … Research Solutions, LLC) owns, develops, implements and supports outcomes and clinical data collection software systems. OBERD optimizes the data collection necessary to empower evidence-based medical practice, improve the quality and efficacy of care, and …

National Institute of Allergy and Infectious Diseases

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19 | Business Wire | 8/10/2020

… clinical studies of Veklury conducted by Gilead and the Phase 3 randomized, placebo-controlled study of Veklury conducted by the National Institute of Allergy and Infectious Diseases (NIAID). These studies demonstrated that treatment with Veklury … Letter of Authorization available at www.gilead.com/remdesivir . There are limited clinical data available for Veklury. Serious and unexpected adverse events may occur that have not been previously reported with Veklury use. Hypersensitivity reactions, including infusion …

HIPAA

TriNetX Commences Chart Review of Hospitalized COVID-19 Patients to Generate Clinically-Enriched, Regulatory-Grade Dataset for Treatment & Vaccine Research | PR Newswire | 7/29/2020

… and CDC. The review protocol has been approved by a central institutional review board (IRB) as being in compliance with HIPAA regulations, and no protected health information (PHI) will be captured. Reviewers will extract over … and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of …

Community Health

16 hospitals, health systems seeking Allscripts, Cerner, Epic, Meditech talent | Becker’s Hospital Review | 7/29/2020

Community Health Northwest Florida (Pensacola): Seeks a patient technical engagement coordinator. 2. Regional One Health (Memphis, Tenn.): Seeks an information systems analyst 3. Cancer Treatment Centers of America (Atlanta): Seeks a radiology systems analyst 4. Flagler Hospital (Saint Augustine, Fla.): Seeks a clinical data engineer Cerner 1. Huntington Hospital (Pasadena, Calif.): Seeks a revenue cycle informatics analyst 2. Texoma Medical Center (Denson, Texas): Seeks a clinical systems analyst 3. Children’s …

Population Health

Jeffrey Koplan and Amelie Ramirez Join CDC Foundation Board of Directors | PR Newswire | 7/29/2020

… vice president for Global Health at Emory University , and Amelie Ramirez , DrPH, MPH, professor and chair of the Department of Population Health Sciences and director of the Institute for Health Promotion Research at UT Health … and chairs the Wellcome Trust’s Independent Review Panel of its Clinical Data Sharing Program. In addition, Koplan is a trustee of the China Medical Board and a former trustee of Yale University and the Robert …

National Library of Medicine

NIH to Host Virtual Community Workshop on Jumpstarting Access to Clinical Data for COVID-19 Research | Data Science at NIH | National Institutes of Health | 7/29/2020

Wednesday, July 29, 2020 NIH to Host Virtual Community Workshop on Jumpstarting Access to Clinical Data for COVID-19 Research Register to Attend Virtually The Office of Data Science Strategy at the National Institutes of Health (NIH) and the National Library of Medicine are hosting a virtual workshop on Jumpstarting Access to Clinical Data for COVID-19 Research on July 29, 2020. NIH is committed to advancing research and its …

Clinical Research

Life Sciences Industry Accelerates Growth and Navigates COVID-19 with eClinical Solutions’ ASCEND Clinical Data Services | PRWeb | 7/23/2020

Life Sciences Industry Accelerates Growth and Navigates COVID-19 with eClinical Solutions’ ASCEND Clinical Data Services Share Article Boston pharma tech innovator supports faster clinical trials and regulatory drug approvals with advanced technology platforms and … by a shared mission of leveraging technology to improve the clinical research process,” said Katrina Rice, EVP, Professional Services, eClinical Solutions. “With seven accreditations across the Medidata Rave Clinical Cloud, eClinical Solutions and ASCEND Clinical …

Teleflex Inc

NeoTract Designates Dr. Ryan Nelson as UroLift® Center of Excellence | PRWeb | 8/21/2020

… care to BPH patients using the UroLift System treatment,” said Dave Amerson PLEASANTON, Calif. NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today … the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and …

Medicomp Systems

Medicomp Systems Introduces Dedicated Care Planning and Documentation Solution for Nurses at 2020 ANIA Annual Conference | PR Newswire | 8/20/2020

WASHINGTON , Aug. 20, Medicomp Systems, the leading provider of clinician-driven, point-of-care solutions that fix EHRs, announced today a new version of Quippe Nursing, the industry’s first dedicated care planning and clinical documentation … CMS and Joint Commission requirements. Through the filtering of relevant clinical data and linking to appropriate Clinical Care Classification (CCC) terminology, nurses can be assured that care plans and documentation are accreditation compliant, audit proof …

Teleflex

NeoTract Designates Dr. Thomas Facelle as UroLift® Center of Excellence | PRWeb | 8/20/2020

… with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson PLEASANTON, Calif. NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today … the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and …

Merck

Merck’s oral cancer drug targeting STING boosts PD-1 immune blockade in mice | FierceBiotech | 8/20/2020

… is one potential strategy that has been shown to stimulate T cell recruitment to the tumor microenvironment. Now, scientists at Merck & Co. have designed a STING agonist that can be taken by mouth. The drug … 200 million upfront deal only to return it after lackluster clinical data. GlaxoSmithKline is developing GSK3745417 , which can be administered intravenously. Bristol Myers Squibb, through its 2017 acquisition of IFM Therapeutics , has BMS-986301 , which …

Novartis

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis | PR Newswire | 8/20/2020

PRNewswire/ – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to … development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally, including European regulatory authorities not approving Kesimpta in the expected time frame, or at all …

Merck & Co

Merck’s oral cancer drug targeting STING boosts PD-1 immune blockade in mice | FierceBiotech | 8/20/2020

… is one potential strategy that has been shown to stimulate T cell recruitment to the tumor microenvironment. Now, scientists at Merck & Co. have designed a STING agonist that can be taken by mouth. The drug … 200 million upfront deal only to return it after lackluster clinical data. GlaxoSmithKline is developing GSK3745417 , which can be administered intravenously. Bristol Myers Squibb, through its 2017 acquisition of IFM Therapeutics , has BMS-986301 , which …

Microsoft Health

So people can just lie to Congress now and nothing happens? - Business Insider | 8/19/2020

clinical data is not yet strong enough to justify the approval. Trump seems to favor Oracle's bid to acquire TikTok's US operations. Oracle boss Larry Ellison is a Trump supporter and donor , and Trump seems to want Oracle, not Microsoft, to acquire ByteDance's US operations. Last week, Trump gave ByteDance 45 days to start a US sale or risk being shut down. VIEWS OF …

Novavax

Novavax Is the Ultimate Coronavirus Stock | MSN | 8/19/2020

Previous Next Novavax Is the Ultimate Coronavirus Stock InvestorPlace 13 hrs ago Dana Blankenhorn © Source: Ascannio/Shutterstock.com Novavax (NVAX) logo surrounded by medical supplies No company was better prepared for the novel coronavirus, than (NASDAQ … 2 trial, which has now begun in South Africa. Early clinical data is encouraging, but it’s early clinical data. RexVax also had positive early clinical data. Novavax isn’t alone in raking in big bucks for …

TriNetX

EY Names TriNetX Chief Executive Officer Gadi Lachman as an Entrepreneur Of The Year® 2020 New England Award Finalist | PR Newswire | 8/19/2020

CAMBRIDGE, Mass. Ernst & Young LLP (EY US) announced that Gadi Lachman, Chief Executive Officer of TriNetX, was named an Entrepreneur Of The Year ® 2020 New England Award finalist. Now in its 34th year, the Entrepreneur … and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of …

CStone Pharmaceuticals

CStone Pharmaceuticals Reports Financial Results for the First Half of 2020 | PR Newswire | 8/19/2020

CStone Pharmaceuticals Reports Financial Results for the First Half of 2020 News provided by Aug 18, 2020, 21:27 ET Share this article Suzhou, China , Aug. 18, 2020 /PRNewswire/ – CStone Pharmaceuticals (“CStone”; HKEX: 2616), a leading … paper describing the full characterization of CS1003 and its pre-clinical data was published on Acta Phamacologica Sinica in May 2020 (Fu et al, 2020 online). Pralsetinib (CS3009, RET inhibitor)- The registrational study of pralsetinib …

National Medical Products Administration

Ascentage Pharma Releases 2020 Interim Results, Reporting the Company’s First New Drug Application and Advances in Global Strategic Collaborations | PR Newswire | 8/18/2020

… the reporting period. In June 2020 , Ascentage Pharma submitted an NDA to the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) for HQP1351 in patients with T315I-mutant chronic phase chronic … in the apoptosis-focused pipeline has delivered marked progress, with clinical data of these products making frequent appearances at major scientific congresses, signifying the company’s growing scientific influence globally. We have advanced global development and …

Pfizer

Times of Global Turmoil Reinforce the Need for Advanced Diagnostic Capabilities | PR Newswire | 8/17/2020

… the virus. Todos Medical Ltd. (OTC: TOMDF), Aytu BioScience, Inc. (NASDAQ: AYTU ), CytoDyn Inc. (OTC: CYDY), iBio, Inc. (NYSE: IBIO ), Pfizer Inc. (NASDAQ: PFE ) The diagnostics test manufacturing industry is under immense pressure due to … datasets are under evaluation. “We are encouraged by these pre-clinical data, which demonstrate IBIO-201’s ability to generate an immune response to SARS-CoV-2 sequences and neutralize protein interaction,” said Tom Isett …

Boston Scientific

BTG Specialty Pharmaceuticals announces the European Medicines Agency has accepted for review a marketing authorisation application for Voraxaze® | PR Newswire | 8/17/2020

Boston Scientific (NYSE: BSX ), today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorisation Application (MAA) for Voraxaze ® (glucarpidase). BTG Specialty Pharmaceuticals is seeking marketing authorization of Voraxaze ® for the treatment of adults and children (from 28 days of age) at risk of methotrexate toxicity due to delayed methotrexate elimination. The MAA for Voraxaze ® is based on clinical data as well as real world experience in …

Celgene

Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program | FierceBiotech | 8/17/2020

… also focusing on a series of solid tumor targets, and builds on the 2017 and 2018 deals Dragonfly penned with Celgene, recently bought out by BMS, which focused on a series of assets for blood … our continued work with Dragonfly to further guide the program’s clinical data at this pivotal point in its development, as we continue to deliver on our commitment to serve more patients with cancer.” “We are …

Medrio

Medrio, Inc. Names Nicole Latimer as Chief Executive Officer | PRWeb | 8/17/2020

Medrio, Inc. Names Nicole Latimer as Chief Executive Officer Share Article Nicole Latimer appointed to Chief Executive Officer of Medrio, Mike Novotny ends his tenure as CEO. “We are fortunate to have someone of Nicole … easy-to-use tools for the collection and management of clinical data and patient-reported outcome responses. Study sponsors and Contract Research Organizations have used Medrio extensively in clinical trials across a wide array of …

Bluebird Bio

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 8/17/2020

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug 17, 2020– bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients … with the U.S. Food and Drug Administration (FDA) that the clinical data package required to support a Biologics Licensing Application (BLA) submission for LentiGlobin for SCD will be based on data from a portion of …

Johnson & Johnson

Sinopharm shares phase 2 data on inactivated COVID-19 vaccine | FierceBiotech | 8/14/2020

Sinopharm has published clinical data on its adjuvanted SARS-CoV-2–inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against … of prophylactic that has never been approved. AstraZeneca, CanSino and Johnson & Johnson are taking a viral vector approach that is barely more established than mRNA. Sinopharm and fellow Chinese’ vaccine developer Sinovac are at the …

AstraZeneca

Sinopharm shares phase 2 data on inactivated COVID-19 vaccine | FierceBiotech | 8/14/2020

Sinopharm has published clinical data on its adjuvanted SARS-CoV-2–inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against … vaccines, a type of prophylactic that has never been approved. AstraZeneca, CanSino and Johnson & Johnson are taking a viral vector approach that is barely more established than mRNA. Sinopharm and fellow Chinese’ vaccine developer Sinovac …

Verona Pharma

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020 | Globe Newswire | 8/14/2020

… to start in the third quarter Conference Call Today at 9:00 am EDT / 2:00 pm BST LONDON and RALEIGH, N.C., Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage … with COVID-19 at the University of Alabama at Birmingham. Clinical data from prior studies of ensifentrine in other respiratory diseases have demonstrated ensifentrine improves lung function and reduces cellular markers of inflammation in the …

BeiGene

Leap Therapeutics Reports Second Quarter 2020 Financial Results | PR Newswire | 8/13/2020

… patients Announced Orphan Drug Designation of DKN-01 for the treatment of gastric and gastroesophageal junction cancer “Our partnership with BeiGene for the clinical development and commercialization of DKN-01 is progressing extremely well, and … Monotherapy and Paclitaxel Combination in Gynecologic Cancers – Leap announced updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, as both a monotherapy and in combination with paclitaxel chemotherapy, in patients with …

Thermo Fisher

Innovative Diagnostic Kits Arise from a Time of Global Turmoil | PR Newswire | 8/13/2020

… back in March. According to the FDA’s announcement, it has issued the fourth diagnostic related Emergency Use Authorization (EUA) to Thermo Fisher for its TaqPath Combo Kit. FDA Commissioner Stephen M. Hahn , M.D explained that … Pharmaceuticals, Inc. (NASDAQ: INO ) announced back in June positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts. In addition …

Inovio

Innovative Diagnostic Kits Arise from a Time of Global Turmoil | PR Newswire | 8/13/2020

… Bio-Medical Science Co., Ltd. (NASDAQ: ANPC ), Moderna, Inc. (NASDAQ: MRNA ), Novavax, Inc. (NASDAQ: NVAX ), Vir Biotechnology, Inc. (NASDAQ: VIR ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ). The Food and Drug Administration (FDA) emphasized the importance of … Pharmaceuticals, Inc. (NASDAQ: INO ) announced back in June positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts. In addition …

Rimidi

Rimidi, LifeQ Partner to Add Wearable-Based Monitoring to Rimidi’s Platform Enabling Early Warning of COVID-19 Infection | PRWeb | 8/13/2020

Rimidi, LifeQ Partner to Add Wearable-Based Monitoring to Rimidi’s Platform Enabling Early Warning of COVID-19 Infection Share Article With the addition of physiological monitoring via LifeQ’s wearable-based platform, businesses can better predict … in connected care by combining patient-generated health data with clinical data from the EHR to drive patient-specific clinical insights and actions. The net effect is a better health system with optimized clinical workflows …

Ionis Pharmaceuticals

Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany | PR Newswire | 8/13/2020

PRNewswire/ – Akcea Therapeutics, Inc. (NASDAQ: AKCA ), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the German Association of Statutory Sick Funds has agreed upon new pricing and reimbursement of WAYLIVRA ® (volanesorsen) as … to offer appropriate patients a treatment option supported by extensive clinical data including results from the Phase 3 APPROACH study,” said Professor Ioanna Gouni-Berthold from University of Cologne . FCS is a debilitating genetic disease …

Inovio Pharmaceuticals

Innovative Diagnostic Kits Arise from a Time of Global Turmoil | PR Newswire | 8/13/2020

… Bio-Medical Science Co., Ltd. (NASDAQ: ANPC ), Moderna, Inc. (NASDAQ: MRNA ), Novavax, Inc. (NASDAQ: NVAX ), Vir Biotechnology, Inc. (NASDAQ: VIR ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ). The Food and Drug Administration (FDA) emphasized the importance of … Pharmaceuticals, Inc. (NASDAQ: INO ) announced back in June positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts. In addition …

Alkermes

Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors | PR Newswire | 8/19/2020

DUBLIN Alkermes plc (Nasdaq: ALKS ) today announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy on the tumor microenvironment of a variety … binding to the intermediate-affinity IL-2 receptor complex. “Early clinical data from our ARTISTRY program showed that ALKS 4230 selectively expanded cancer-fighting immune cells in the periphery, with negligible effects on regulatory T …

Atlas Venture

Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates | PR Newswire | 8/12/2020

… Ph.D., President and CEO of Unum. “PLX9486 is a highly potent and selective KIT D816V inhibitor that has demonstrated promising clinical data, and we believe has significant potential to transform the management of serious diseases … with participation from Venrock Healthcare Capital Partners, BVF Partners L.P., Atlas Venture, Acorn Bioventures, Perceptive Advisor’s LLC, RTW Investments, OrbiMed, Samsara BioCapital, Logos Capital, Ally Bridge Group and Commodore Capital, as well as additional undisclosed …

Venrock

Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates | PR Newswire | 8/12/2020

… Ph.D., President and CEO of Unum. “PLX9486 is a highly potent and selective KIT D816V inhibitor that has demonstrated promising clinical data, and we believe has significant potential to transform the management of serious diseases … was led by Fairmount Funds Management LLC, with participation from Venrock Healthcare Capital Partners, BVF Partners L.P., Atlas Venture, Acorn Bioventures, Perceptive Advisor’s LLC, RTW Investments, OrbiMed, Samsara BioCapital, Logos Capital, Ally Bridge Group and …

Zacks Investment Research

Change Healthcare reports better-than-expected results despite the impact of COVID-19 pandemic | FierceHealthcare | 8/10/2020

… nonrecurring costs and stock option expense, came to 25 cents per share. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 15 cents per share. Adjusted earnings came to … hotel room or rental car. Change Healthcare also launched a clinical data retrieval service, a new cloud-based interoperability solution that makes it easy for payers to instantly retrieve patient records from virtually any electronic …

Foresite Capital

Tasso secures $17M to scale up home blood testing devices in the face of COVID-19 | FierceBiotech | 7/27/2020

… for analysis. The Seattle-based company’s series A round was led by Hambrecht Ducera Growth Ventures, with additional backing from Foresite Capital, Merck’s Global Health Innovation Fund, Vertical Venture Partners, Techstars and Cedars-Sinai. The … patient-centric approaches to enable collection of reliable and actionable clinical data.” In 2017 , Tasso received funding from the U.S. Army’s medical research institute through a collaboration developing a surveillance platform for infectious disease outbreaks …

SVB Leerink

Want widespread COVID-19 vaccine adoption? Be transparent about clinical data, experts say | FiercePharma | 7/17/2020

Want widespread COVID-19 vaccine adoption? Be transparent about clinical data, experts say by Angus Liu Jul 20, 2020 3:50am COVID-19 herd immunity through vaccination will depend heavily on transparent communication with the general public, two experts said at a recent SVB Leerink event. (Getty Images) Many biopharma companies have been talking up the potential of authorized COVID-19 vaccines by year-end. But experts caution that a rushed …

Google Ventures

GV-backed startup inks deal with urology docs to advance new treatments | FierceHealthcare | 6/24/2020

clinical data registry. The registry features clinical data from more than 6.3 million unique patients and 37.8 million visits, including 10% of the nation’s prostate cancer patients. The San Francisco-based startup—which is backed by GV, formerly known as Google Ventures—partners with medical associations to analyze large data sets of de-identified patient data in eye diseases, neurology and now urology. This information can accelerate the development of …

Optum Ventures

$13.5M for Binah.ai, $35M for Abacus Insights and more digital health fundings | MobiHealthNews | 6/22/2020

Also: Optum Ventures leads unspecified investment into DocASAP; Wellsheet to build up engineering and go-to-market teams with $3.8 million Series A. 01:56 pm Share Binah.ai has raised $13.5 million in Series B funding … Tel Aviv, Israel-based startup using AI to format unstructured clinical data, has raised a $3 million seed round led by MMC Ventures, with contributions from InHealth Ventures, Seedcamp and Bayer G4A. The company will …

Morgan Stanley

NewYork-Presbyterian Ranked Among Nation’s “Best Children’s Hospitals” by U.S. News & World Report | PR Newswire | 6/16/2020

… cardiology and heart surgery. NewYork-Presbyterian provides pediatric care in every area of medicine at two major sites: NewYork-Presbyterian Morgan Stanley Children’s Hospital and NewYork-Presbyterian Komansky Children’s Hospital . NewYork-Presbyterian is the nation’s … family.” The U.S. News “Best Children’s Hospitals” rankings rely on clinical data and on an annual survey of pediatric specialists. The rankings methodology factors in patient outcomes, clinical services and processes, and compliance with best …

NCI

Vivera Pharmaceuticals Issues Response to Recent Article | PR Newswire | 6/16/2020

… clinical data, which we would have gladly provided to him just as we have provided to the FDA. Vivera has voluntarily participated in the FDA and NCI third-party validation testing. Why would we do that if we did not stand behind the results?” Vivera has issued a full statement on its website at: https://www.viverapharmaceuticals.com/news https://www.viverapharmaceuticals.com/news-media/press-releases/detail/46/vivera-pharmaceuticals-statement-on-recent …

JP Morgan

Edited Transcript of IONS earnings conference call or presentation 6-May-20 3:30pm GMT | Yahoo News | 5/25/2020

… Senior Biotechnology Analyst James William Birchenough Wells Fargo Securities, LLC, Research Division - MD and Senior Biotechnology Analyst Jessica Macomber Fye JP Morgan Chase & Co, Research Division - Analyst Joshua Elliott Schimmer Evercore ISI Institutional Equities, Research … future. This is the first. It’s targeting ataxin-2. The preclinical data looks very exciting and compelling, and one of our key objectives this year is to get the clinical study started with Biogen. As …

Needham & Company

Edited Transcript of IONS earnings conference call or presentation 6-May-20 3:30pm GMT | Yahoo News | 5/25/2020

… Inc. - EVP of Development Conference Call Participants Alexander Thompson Stifel, Nicolaus & Company, Incorporated, Research Division - Research Analyst Chad Jason Messer Needham & Company, LLC, Research Division - Senior Analyst Eliana Rachel Merle Cantor Fitzgerald & Co., Research Division … future. This is the first. It’s targeting ataxin-2. The preclinical data looks very exciting and compelling, and one of our key objectives this year is to get the clinical study started with Biogen. As …

Wells Fargo Securities

Edited Transcript of IONS earnings conference call or presentation 6-May-20 3:30pm GMT | Yahoo News | 5/25/2020

… Analyst I-Eh Jen Laidlaw & Company (UK) Ltd., Research Division - MD of Healthcare Research & Senior Biotechnology Analyst James William Birchenough Wells Fargo Securities, LLC, Research Division - MD and Senior Biotechnology Analyst Jessica Macomber Fye JP … future. This is the first. It’s targeting ataxin-2. The preclinical data looks very exciting and compelling, and one of our key objectives this year is to get the clinical study started with Biogen. As …

Cowen and Company

Edited Transcript of IONS earnings conference call or presentation 6-May-20 3:30pm GMT | Yahoo News | 5/25/2020

… Institutional Equities, Research Division - Senior MD & Equity Analyst Rick Stephen Bienkowski SVB Leerink LLC, Research Division - Associate Ritu Subhalaksmi Baral Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst Tyler Martin Van Buren Piper … future. This is the first. It’s targeting ataxin-2. The preclinical data looks very exciting and compelling, and one of our key objectives this year is to get the clinical study started with Biogen. As …

JP Morgan Chase

Edited Transcript of IONS earnings conference call or presentation 6-May-20 3:30pm GMT | Yahoo News | 5/25/2020

… Senior Biotechnology Analyst James William Birchenough Wells Fargo Securities, LLC, Research Division - MD and Senior Biotechnology Analyst Jessica Macomber Fye JP Morgan Chase & Co, Research Division - Analyst Joshua Elliott Schimmer Evercore ISI Institutional Equities, Research … future. This is the first. It’s targeting ataxin-2. The preclinical data looks very exciting and compelling, and one of our key objectives this year is to get the clinical study started with Biogen. As …

OrbiMed Advisors

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results | Globe Newswire | 5/22/2020

… Chief Executive Officer of Kinnate Biopharma Inc., and Carl Gordon, Managing Partner and Co-Head of Global Private Equity at OrbiMed Advisors LLC, to its board of directors. Recent Program Highlights: KER-050 for the … trials, business and operations; Keros’ plans to present preclinical and clinical data at upcoming conferences; and Keros’ expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from …

Maxim Group

Applied DNA to Participate in Maxim Group’s COVID-19 Virtual Conference Series on May 27 | Yahoo News | 5/21/2020

… a panel titled ‘COVID-19 Testing and Monitoring’ at 12:15 p.m. ET on Wednesday, May 27, 2020 as part of Maxim Group’s COVID-19 Virtual Conference Series. The panel will be moderated by Jason McCarthy … market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s or its partners diagnostic or therapeutic candidates will advance further in the preclinical research or …

Goldman Sachs

Moderna’s stock soars, then dips, after questions arise around the limited data shared about its COVID-19 vaccine | MarketWatch | 5/20/2020

… of Moderna closed at a record high of $80.00 on Monday after the company released a slice of positive interim clinical data from the first phase of its COVID-19 vaccine trial. That night it … view this data as demonstrative of early signs of efficacy,” Goldman Sachs analysts wrote in an investor note on Monday …

William Blair

Edited Transcript of PTCT earnings conference call or presentation 30-Apr-20 8:30pm GMT | Yahoo News | 5/18/2020

… Watsek Cantor Fitzgerald & Co., Research Division - Research Analyst Peter B. Kim Barclays Bank PLC, Research Division - Analyst Raju Yashaswi Prasad William Blair & Company L.L.C., Research Division - Senior Research Analyst Tazeen Ahmad BofA Merrill Lynch, Research … third quarter. We expect that in combination with our existing clinical data, statistically significant results in 045 would be sufficient for accelerated approval in the U.S. As a reminder, this is a single-site, 40 …

Merrill Lynch

Edited Transcript of PTCT earnings conference call or presentation 30-Apr-20 8:30pm GMT | Yahoo News | 5/18/2020

… Bank PLC, Research Division - Analyst Raju Yashaswi Prasad William Blair & Company L.L.C., Research Division - Senior Research Analyst Tazeen Ahmad BofA Merrill Lynch, Research Division - VP Vincent Chen Sanford C. Bernstein & Co., LLC., Research Division - VP … third quarter. We expect that in combination with our existing clinical data, statistically significant results in 045 would be sufficient for accelerated approval in the U.S. As a reminder, this is a single-site, 40 …

RBC Capital Markets

Edited Transcript of PTCT earnings conference call or presentation 30-Apr-20 8:30pm GMT | Yahoo News | 5/18/2020

… Chief Development Officer Stuart W. Peltz PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director Conference Call Participants Gilbert Roland Kinsey RBC Capital Markets, Research Division - Senior Associate Joel Lawrence Beatty Citigroup Inc, Research Division - VP … third quarter. We expect that in combination with our existing clinical data, statistically significant results in 045 would be sufficient for accelerated approval in the U.S. As a reminder, this is a single-site, 40 …

Citigroup

Edited Transcript of PTCT earnings conference call or presentation 30-Apr-20 8:30pm GMT | Yahoo News | 5/18/2020

… Founder, CEO & Executive Director Conference Call Participants Gilbert Roland Kinsey RBC Capital Markets, Research Division - Senior Associate Joel Lawrence Beatty Citigroup Inc, Research Division - VP & Analyst Joseph John-Charles Thome Cowen and Company, LLC, Research … third quarter. We expect that in combination with our existing clinical data, statistically significant results in 045 would be sufficient for accelerated approval in the U.S. As a reminder, this is a single-site, 40 …

Cantor Fitzgerald

Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology and the Janssen Oncology Strategy and Portfolio | PR Newswire | 5/18/2020

NEW BRUNSWICK, N.J. , May 18, 2020 /PRNewswire/ – The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ ) will participate in a pre-recorded fireside chat webcast hosted by Cantor Fitzgerald focused on clinical data being presented at the virtual 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast is intended for investors and other interested parties, and will be available beginning at 8:00a.m ET on Tuesday, May 19, 2020 …

Silicon Valley Bank

TRACON Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update | Globe Newswire | 5/13/2020

… the androgen receptor inhibitors Xtandi and Erleada are not widely accessible. In April, TRACON entered into a deferral agreement with Silicon Valley Bank to defer principal payments for six months, which is expected to extend … of TRACON. “We look forward to the presentation of envafolimab clinical data by our corporate partner, 3D Medicines, at ASCO, enrolling the first ENVASARC patient in the second half of this year, and potentially becoming …

Sequoia Capital

Ex-Sequoia VC Michael Dixon on digital health investment strategy - Business Insider | 12/4/2019

Michael Dixon , who spent 10 years at Sequoia Capital , is joining a new venture fund focused on digital health. Dixon is joining up with the Sequoia alum Todd Cozzens and Dr. Jared Kesselheim at Transformation … said. Then, there are pharmaceutical companies looking to use digitized clinical data to aid in developing new treatments. “Now that we have clinical data, pharmaceutical companies are reimagining their business,” Dixon said. Already, Transformation Capital …

Carilion Clinic

Wolters Kluwer Adds AI to Clinical Surveillance for Faster C. Difficile Infection Prediction | Business Wire | 8/20/2020

Carilion Clinic quickly saw its value. “As a multi-hospital system, we face a unique set of challenges in managing patient safety, regulatory compliance and costs, and reducing C. diff infections remains a focus of ours,” said Caitlin Meanor, Infectious Diseases Pharmacist at Carilion. “With the CDI Risk Score embedded in Sentri7, we can harness all of the clinical data associated with patient care and allow our clinical pharmacists to …

Harvard Medical School

Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors | Globe Newswire | 8/19/2020

… Mass., Aug. 19, Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics at Anthem, to its Board of Directors. “We are delighted to welcome … in Human Biology from Stanford University and her MD from Harvard Medical School. She holds an MBA from Harvard Business School and an MPH from Harvard TH Chan School of Public Health. She completed her …

Massachusetts General Hospital

CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11 | PR Newswire | 8/18/2020

… multiple treatment cycles where indicated for both future preconditioning and no-preconditioning patients. New clinical sites for the study at Massachusetts General Hospital/ Harvard Medical School and Hackensack University Medical Center are joining existing sites … abstract . Following the expansion of the Phase I trial, preliminary clinical data for the existing no-preconditioning MCY-M11 trial are anticipated in H2 2020. “We are very pleased with the progress of this first …

Hackensack University Medical Center

CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11 | PR Newswire | 8/18/2020

… future preconditioning and no-preconditioning patients. New clinical sites for the study at Massachusetts General Hospital/ Harvard Medical School and Hackensack University Medical Center are joining existing sites at the National Cancer Institute at the … abstract . Following the expansion of the Phase I trial, preliminary clinical data for the existing no-preconditioning MCY-M11 trial are anticipated in H2 2020. “We are very pleased with the progress of this first …

Medical Center

CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11 | PR Newswire | 8/18/2020

… and no-preconditioning patients. New clinical sites for the study at Massachusetts General Hospital/ Harvard Medical School and Hackensack University Medical Center are joining existing sites at the National Cancer Institute at the National Institutes … abstract . Following the expansion of the Phase I trial, preliminary clinical data for the existing no-preconditioning MCY-M11 trial are anticipated in H2 2020. “We are very pleased with the progress of this first …

University Medical Center

CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11 | PR Newswire | 8/18/2020

… preconditioning and no-preconditioning patients. New clinical sites for the study at Massachusetts General Hospital/ Harvard Medical School and Hackensack University Medical Center are joining existing sites at the National Cancer Institute at the National … abstract . Following the expansion of the Phase I trial, preliminary clinical data for the existing no-preconditioning MCY-M11 trial are anticipated in H2 2020. “We are very pleased with the progress of this first …

Hackensack University Medical Center, Hackensack NJ

CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11 | PR Newswire | 8/18/2020

… future preconditioning and no-preconditioning patients. New clinical sites for the study at Massachusetts General Hospital/ Harvard Medical School and Hackensack University Medical Center are joining existing sites at the National Cancer Institute at the … abstract . Following the expansion of the Phase I trial, preliminary clinical data for the existing no-preconditioning MCY-M11 trial are anticipated in H2 2020. “We are very pleased with the progress of this first …

Memorial Sloan Kettering Cancer Center

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 8/17/2020

… cerebral disease status (ALD-103) Presenting Author: Dr. Jaap Jan Boelens, Chief, Pediatric Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center Poster Session & Number: Haemoglobinopathy and inborn errors; ePoster O106 Multiple … with the U.S. Food and Drug Administration (FDA) that the clinical data package required to support a Biologics Licensing Application (BLA) submission for LentiGlobin for SCD will be based on data from a portion of …

Memorial Sloan Kettering

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 8/17/2020

… cerebral disease status (ALD-103) Presenting Author: Dr. Jaap Jan Boelens, Chief, Pediatric Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center Poster Session & Number: Haemoglobinopathy and inborn errors; ePoster O106 Multiple … with the U.S. Food and Drug Administration (FDA) that the clinical data package required to support a Biologics Licensing Application (BLA) submission for LentiGlobin for SCD will be based on data from a portion of …

Columbia University Medical Center

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 8/17/2020

… from the Phase 1/2 HGB-206 study Presenting Author: Dr. Markus Y. Mapara, Director, Adult Blood and Marrow Transplantation Program, Columbia University Medical Center Oral Session & Number: Inborn Errors; O080 Date & Time: September 1, 2020 … with the U.S. Food and Drug Administration (FDA) that the clinical data package required to support a Biologics Licensing Application (BLA) submission for LentiGlobin for SCD will be based on data from a portion of …

Sutter Health

COVID Data Failures Create Pressure for Public Health System Overhaul | Kaiser Health News | 8/14/2020

Sutter Health and UC Davis Health, along with nearly 30 other provider organizations around the country, recently launched a href=”https://www.healthaffairs.org/do/10.1377/hblog20200729.517619/full/” a collaborative effort /a to speed and improve the sharing of clinical data on individual COVID cases with public health departments. /p p But even that platform, which contains information about patients’ diagnoses and response to treatments, doesn’t yet include data on the availability …

Cleveland Clinic

16 hospitals, health systems seeking Allscripts, Cerner, Epic, Meditech talent | Becker’s Hospital Review | 8/13/2020

clinical data engineer 4. PIH Health (Whittier, Calif.): Seeks a revenue cycle system implementation assistant director Cerner 1. Mon Health (Morgantown, W.Va.): Seeks an application analyst 2. Universal Health Services (King of Prussia, Pa.): Seeks an information services integration manager 3. Ranken Jordan Pediatric Bridge Hospital (Maryland Heights, Mo.): Seeks an IT clinical analyst 4. Lodi (Calif.) Memorial Hospital Association: Seeks a quality analyst Epic 1. Cleveland Clinic: Seeks an …

Children's Hospital

Researchers Combine Genetic Information with Electronic Medical Records to Pinpoint When Epilepsies Affect Children | PR Newswire | 8/11/2020

PHILADELPHIA A team of researchers at Children’s Hospital of Philadelphia (CHOP) affiliated with the CHOP Epilepsy Neurogenetics Initiative (ENGIN) further bridged the gap between genomic information and clinical outcome data by systematically linking genetic information … assessing more than 3,200 observational patient years, an amount of clinical data far beyond what could have been reviewed through manual chart review. “With new precision therapies emerging, there is a pressing demand to understand …

Children's Hospital of Philadelphia

Researchers Combine Genetic Information with Electronic Medical Records to Pinpoint When Epilepsies Affect Children | PR Newswire | 8/11/2020

PHILADELPHIA A team of researchers at Children’s Hospital of Philadelphia (CHOP) affiliated with the CHOP Epilepsy Neurogenetics Initiative (ENGIN) further bridged the gap between genomic information and clinical outcome data by systematically linking genetic information … assessing more than 3,200 observational patient years, an amount of clinical data far beyond what could have been reviewed through manual chart review. “With new precision therapies emerging, there is a pressing demand to understand …

Stanford Medicine

Stanford Center for Health Education Launches Online Program in Artificial Intelligence in Healthcare to Improve Patient Outcomes | PR Newswire | 8/10/2020

… patient care and improve global health outcomes through artificial intelligence and machine learning. The online program, taught by faculty from Stanford Medicine , is designed for healthcare providers, technology professionals, and computer scientists. The goal is … AI in Healthcare specialization are: Introduction to Healthcare, Introduction to Clinical Data, Fundamentals of Machine Learning for Healthcare, and Evaluations of AI Applications in Healthcare. SOURCE Stanford Center for Health Education …

University Hospital

Enterome initiates first clinical trial with EO2401 - an innovative microbiome-antigen (‘OncoMimic’) based cancer immunotherapy candidate targeting aggressive brain cancer | PR Newswire | 7/30/2020

… for progressive or first recurrent glioblastoma multiforme (GBM), an aggressive form of brain cancer for which no cure exists. Initial clinical data from the ROSALIE study are expected in 2022. EO2401 is an innovative, off … US. Prof. Wolfgang Wick , MD, Chairman, Department of Neurology, Heidelberg University Hospital (Heidelberg, Germany ), is ROSALIE’s Principal Investigator. Professor Wick is a globally renowned neuro-oncologist with extensive clinical research experience in the field of …

Nationwide Children's Hospital

16 hospitals, health systems seeking Allscripts, Cerner, Epic, Meditech talent | Becker’s Hospital Review | 7/29/2020

… 3. Cancer Treatment Centers of America (Atlanta): Seeks a radiology systems analyst 4. Flagler Hospital (Saint Augustine, Fla.): Seeks a clinical data engineer Cerner 1. Huntington Hospital (Pasadena, Calif.): Seeks a revenue cycle informatics analyst … Valley Health System (Fayetteville, N.C.): Seeks an applications analyst 4. Nationwide Children’s Hospital (Columbus, Ohio): Seeks a health information management data imaging and quality specialist Meditech 1. Boulder (Colo.) Community Health: Seeks a health information …

MD Anderson Cancer Center

Genocea Biosciences Provides Clinical Update | Globe Newswire | 7/20/2020

clinical data on the first 5 patients from Part B of the ongoing Phase 1/2a clinical trial exploring the combination of GEN-009 and immune checkpoint inhibitor-based regimens in advanced solid tumors. The lead investigator, Dr. Maura L. Gillison, MD, PhD, Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center, will present. GEN-011 In June 2020, the Company submitted the IND …

Mount Sinai Health System

‘It’s about being more agile to meet business needs’: Mount Sinai CIO Kristin Myers outlines opportunities in digital transformation | Becker’s Hospital Review | 6/23/2020

New York City-based Mount Sinai Health System named Kristin Myers executive vice president, CIO and dean of IT in early June. Ms. Myers has spent the past 16 years with the health system, leading … to catch up in healthcare. The ability to take our clinical data and use it for research and potentially create new medications and drugs with machine learning is a tremendous opportunity. The challenge with artificial …

Sinai Health System

‘It’s about being more agile to meet business needs’: Mount Sinai CIO Kristin Myers outlines opportunities in digital transformation | Becker’s Hospital Review | 6/23/2020

New York City-based Mount Sinai Health System named Kristin Myers executive vice president, CIO and dean of IT in early June. Ms. Myers has spent the past 16 years with the health system, leading … to catch up in healthcare. The ability to take our clinical data and use it for research and potentially create new medications and drugs with machine learning is a tremendous opportunity. The challenge with artificial …

Children's Hospital, New Orleans LA

Atrium Health’s Levine Children’s Hospital Named a “Best Children’s Hospital” for 13th Consecutive Year | PR Newswire | 6/23/2020

CHARLOTTE, N.C. , June 23, For the 13 th consecutive year, Atrium Health’s Levine Children’s Hospital has been recognized as one of the best places to care for children in the nation by U.S. News & World … information on U.S. pediatric hospitals. They are compiled from key clinical data from nearly 200 medical centers through a detailed survey that looks at measures such as reputation, patient and family satisfaction, patient safety and …

Children's Hospital, Sewickley PA

Atrium Health’s Levine Children’s Hospital Named a “Best Children’s Hospital” for 13th Consecutive Year | PR Newswire | 6/23/2020

CHARLOTTE, N.C. , June 23, For the 13 th consecutive year, Atrium Health’s Levine Children’s Hospital has been recognized as one of the best places to care for children in the nation by U.S. News & World … information on U.S. pediatric hospitals. They are compiled from key clinical data from nearly 200 medical centers through a detailed survey that looks at measures such as reputation, patient and family satisfaction, patient safety and …

Children's Hospital, Mission Viejo CA

Atrium Health’s Levine Children’s Hospital Named a “Best Children’s Hospital” for 13th Consecutive Year | PR Newswire | 6/23/2020

CHARLOTTE, N.C. , June 23, For the 13 th consecutive year, Atrium Health’s Levine Children’s Hospital has been recognized as one of the best places to care for children in the nation by U.S. News & World … information on U.S. pediatric hospitals. They are compiled from key clinical data from nearly 200 medical centers through a detailed survey that looks at measures such as reputation, patient and family satisfaction, patient safety and …

Department of Veterans Affairs

VHA launches analytics challenge to predict COVID-19 outcomes | Healthcare IT News | 6/22/2020

… 19 status, length of hospitalization and mortality. June 22, 2020 09:44 AM The Veterans Health Administration, part of the U.S. Department of Veterans Affairs, is calling for members of the public to develop machine learning … at Mount Sinai Health System used AI alongside imaging and clinical data to diagnose patients with COVID-19 at a rate comparable to – and in some cases better than – experienced radiologists. ON THE RECORD “The …

CommonSpirit Health

CommonSpirit Uses Predictive Modeling Tools to Forecast COVID-19 Cases | Business Wire | 6/22/2020

CHICAGO–(BUSINESS WIRE)–Jun 22, 2020– CommonSpirit Health , which has 137 hospitals and more than 1,000 care sites serving patients across 21 states, is using de-identified cell phone data, public health data, and data … health care services,” said Dr. Joseph Colorafi, System VP of Clinical Data Science for CommonSpirit Health. “We need to be prepared for asynchronous waves of COVID-19 patients in different regions until a higher level …

Health Net

KeyHIE Taps Longstanding Partnership with Orion Health to Rapidly Enable Public Health Reporting Amid COVID-19 Crisis | Business & Finance | heraldchronicle.com | Business Wire | 6/16/2020

… Health Network with providers and public health entities. KeyHIE turned to longtime technology partner Orion Health to provide project management and interface development services. Responding to the urgent need, Orion Health completed the implementation in just five days. Now, Allegheny’s COVID-19 reportable lab results are instantly shared with other providers in the HIE, stored in the KeyHIE Clinical Data Repository powered by Orion Health, and routed to the Commonwealth …

Harvard Pilgrim Health Care

TriNetX & Harvard Pilgrim Health Care Institute Partner on FDA Sentinel System to Monitor COVID-19 Drug Usage | PR Newswire | 5/21/2020

CAMBRIDGE, Mass. TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE) is working with the FDA Sentinel Operations Center at the Harvard Pilgrim Health Care Institute (HPHCI) to monitor priority drugs used for the care of hospitalized COVID-19 patients. HPHCI is leveraging TriNetX’s de-identified COVID-19 clinical data set to support studies aimed to sequentially monitor …

Humana

Humana and Healthmap Solutions Sign Agreement for Kidney Disease Care Coordination Services in Florida | Business & Finance | heraldchronicle.com | Business Wire | 5/20/2020

Humana and Healthmap Solutions Sign Agreement for Kidney Disease Care Coordination Services in Florida May 20, 2020 Save LOUISVILLE, Ky. & TAMPA, Fla.–(BUSINESS WIRE)–May 20, 2020– Leading health and well-being company Humana Inc … Healthmap Solutions looks forward to applying our expertise in utilizing clinical data and analytics, and our care management experience, to help Humana members stay as healthy as possible.” About Healthmap Solutions, Inc. Healthmap Solutions is …

Clover Health

Can API vendors solve healthcare’s data woes? | TechCrunch | 4/29/2020

… Startup Health, Collaborative Fund, Story Ventures and Company Ventures, as well as angel investors from the leadership of Flatiron Health, Clover Health, Plaid, Petal and Hometeam. Image via Getty Images / OstapenkoOlena “My first reaction when … potentially linking them — and the health data they collect — with clinical data used by physicians to actually make care and treatment decisions. Most devices today are not clinically recognized and don’t have any real integration …

Aetna

Introducing Well: A Platform To Engage And Improve Employee Health | PR Newswire | 11/14/2019

… clinical data, medical experience and dynamic incentives to improve employee health and lower costs.” Loveman led Caesars Entertainment and its more than 70,000 employees for 13 years. Subsequent to his tenure at Caesars, Loveman was President of Consumer Health at Aetna. The Well platform targets engagement with all employees and will initially be offered to employers to include as part of their employee benefit offerings. The company, based in Chapel …

Cigna

SI-BONE, Inc.’s (SIBN) CEO Jeff Dunn on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/12/2019

… the procedure. The study further supports the benefits of minimally invasive SI joint fusion with iFuse. We believe our superior clinical data is a key component of growing positive support from clinical evaluation organizations and … part of next year that’s what we are hearing. At Cigna they are on review right now and as we have shared with you, they took that to their monthly meeting. And we have had …

Health New England

SI-BONE, Inc.’s (SIBN) CEO Jeff Dunn on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/12/2019

clinical data is a key component of growing positive support from clinical evaluation organizations and garnering payer wins, many of which are exclusive to iFuse based on this clinic evidence. Effective July 1, 2019, Vermont, Blue Cross, Blue Shield, which ensures approximately 1.5 million members in South Dakota and Iowa establish positive coverage for minimally invasive SI joint fusion. Additionally, effective September 1, 2019, Health New England, which ensures approximately …

Wellmark Blue Cross Blue Shield

SI-BONE, Inc. Reports Third Quarter 2019 Financial Results and Updates Full-Year 2019 Revenue Guidance | Globe Newswire | 11/11/2019

… patients treated with iFuse Implant System, showing continued durability of clinical response and positive radiographic outcomes Obtained positive coverage from Wellmark Blue Cross Blue Shield for 1.5 million members in South Dakota and Iowa and … the U.S. with the publication of our five-year prospective clinical data. We are also pleased with the decision by Medicare to increase the surgeon payment from $720 to $915 effective January 1, 2020, recognizing …

Anthem Blue Cross

Telehealth eliminates time and distance to save money | Healthcare Finance | 10/16/2019

… primary care doctor or go to urgent care or the emergency room, according to Maria Proulx, regional vice president Sales, Anthem Blue Cross Blue Shield of New Hampshire and former VP of Segment Solutions. “I … use electronic health records (EHRs) to collect and report on clinical data, practices often need help deciding what data to collect, which measures to report … Breaking News. In-Depth Reporting. Best Practices. Delivered to your …

UnitedHealthcare

Diameter Health Names Terry Boch Chief Commercial Officer | 10/4/2019

Former IBM Watson Health and UnitedHealthcare Executive Brings Decades of Experience in Accelerating Healthcare Transformation to Leading Provider of Clinical Data Refinement FARMINGTON, Conn. Diameter Health , the company that cures clinical data disorder, today announced the appointment of Terry Boch as chief commercial officer, responsible for the company’s revenue-generating functions. Boch is a proven leader with over 30 years’ experience in healthcare IT. Her most recent position was vice …

Inland Empire Health Plan

Digital health records are bringing better care and less cost to California consumers | The Business Journals | 9/11/2019

… Academic studies show that the data networks are contributing to significant improvements in patient care through giving providers access to clinical data critical for treating patients in the hospital, an emergency room, in an ambulatory … provider groups and health plans including Blue Shield of California, Inland Empire Health Plan and Anthem. Most recently, Stanford Health Care, San Diego-based Scripps Health, Southern California hospital network AHMC Healthcare, Northridge-based Heritage …

Hometown Health

Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH) | Health IT Outcomes | 7/11/2019

… global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health … largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care …

Network Health

Network Health Expands Relationship with Inovalon | Globe Newswire | 6/19/2019

Leading Health Plan Extends Engagement and Adds CDEaaS™ and NLPaaS™ to Enable Fully Automated Capture and Analysis of Structured and Unstructured Clinical Data at Large Scale June 19, 2019 07:55 ET Source: Inovalon Holdings, Inc. BOWIE, Md., June 19, 2019 (GLOBE NEWSWIRE) – Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Network Health, an innovative health plan serving Medicare, ACA and Commercial …

Capital Blue Cross

New Clinical Data and Insurance Coverage Support Mederi’s Stretta Therapy for GERD | PR Newswire | 11/8/2017

Nov 08, 2017, 07:11 RCT shows Stretta wins over PPI, and new coverage policy issued by Capital Blue Cross in PA NORWALK, Conn. , Nov. 8, 2017 /PRNewswire/ – Mederi is pleased to announce publication of a new randomized, controlled trial as well as additional insurance coverage for Stretta Therapy , a treatment for Gastroesophageal Reflux Disease (GERD). Stretta is a non-surgical, endoscopic, outpatient treatment for GERD that delivers low levels of …

Dave Amerson

NeoTract Designates Dr. Ryan Nelson as UroLift® Center of Excellence | PRWeb | 8/21/2020

… UroLift Center of Excellence for his commitment to providing consistent care to BPH patients using the UroLift System treatment,” said Dave Amerson PLEASANTON, Calif. NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused … the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and …

Donald Trump

First Edition: Aug. 21, 2020 - Kaiser Health News | 8/21/2020

… year they cannot chatter on live television — and to the party truly being united in its desire to defeat President Donald Trump in November. Meanwhile, the coronavirus pandemic continues to complicate efforts around the country … in JAMA, described studying self-collected and mailed samples and clinical data gathered through phone interviews from Mar 27 to May 6. The mothers’ babies ranged in age from newborn to 19 months, and each …

Anthony Fauci

First Edition: Aug. 21, 2020 - Kaiser Health News | 8/21/2020

… orders that they stay closed.But public health experts and top health officials, including the nation’s top infectious diseases official, Dr. Anthony Fauci, have said: When bars open, infections tend to follow. (Stone, 8/21) Kaiser Health … in JAMA, described studying self-collected and mailed samples and clinical data gathered through phone interviews from Mar 27 to May 6. The mothers’ babies ranged in age from newborn to 19 months, and each …

David Lareau

Medicomp Systems Introduces Dedicated Care Planning and Documentation Solution for Nurses at 2020 ANIA Annual Conference | PR Newswire | 8/20/2020

… solution, which is designed to meet the unique documentation, care planning and compliance needs of nurses in the U.S.,” said David Lareau , Medicomp CEO. “Like our other Quippe solutions, Quippe Nursing is powered by Medicomp’s … CMS and Joint Commission requirements. Through the filtering of relevant clinical data and linking to appropriate Clinical Care Classification (CCC) terminology, nurses can be assured that care plans and documentation are accreditation compliant, audit proof …

Seema Verma

What the Interoperability Rule Will Mean for Payers in 2021 | HealthPayer Intelligence | 8/20/2020

… extensive steps CMS has taken to ease the burden on the healthcare industry as it fights COVID-19,” CMS Administrator Seema Verma said at the time. The implications for payers in 2021 The CMS final … share data on provider payer amounts, patient cost-sharing information, clinical data points, and more. Importantly, payers cannot require members to use payer apps. Web-based technology will be in competition with third-party vendors …

Danielle Antalffy

3 “Strong Buy” Penny Stocks With Substantial Upside Potential | Yahoo News | 8/20/2020

Danielle Antalffy likes what she has been seeing. Now that the meeting has been confirmed, Antalffy argues it “essentially implies that FDA views the existing Reducer clinical data as sufficient for approval.” The analyst added, “… we are now increasingly confident that Reducer could secure a U.S. approval in the near-term and launch in early 2021. Given that the NVCN story has been so laser-focused on the Tiara TMVR …

Frank Jiang

CStone Pharmaceuticals Reports Financial Results for the First Half of 2020 | PR Newswire | 8/19/2020

… IO) therapies and precision medicines, today reported recent business highlights and financial results for the first half of 2020. Dr. Frank Jiang , Chairman and Chief Executive Officer of CStone Pharmaceuticals, said, “We continued to make … paper describing the full characterization of CS1003 and its pre-clinical data was published on Acta Phamacologica Sinica in May 2020 (Fu et al, 2020 online). Pralsetinib (CS3009, RET inhibitor)- The registrational study of pralsetinib …

Craig Hopkinson

Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors | PR Newswire | 8/19/2020

clinical data from our ARTISTRY program showed that ALKS 4230 selectively expanded cancer-fighting immune cells in the periphery, with negligible effects on regulatory T cells (Tregs),” said Craig Hopkinson , M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes. “Data from the ARTISTRY-3 clinical trial will provide a deeper understanding of the effects of ALKS 4230 on immunologic activity in the tumor microenvironment across a …

Gadi Lachman

EY Names TriNetX Chief Executive Officer Gadi Lachman as an Entrepreneur Of The Year® 2020 New England Award Finalist | PR Newswire | 8/19/2020

CAMBRIDGE, Mass. Ernst & Young LLP (EY US) announced that Gadi Lachman, Chief Executive Officer of TriNetX, was named an Entrepreneur Of The Year ® 2020 New England Award finalist. Now in its 34th year, the Entrepreneur … and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of …

Elizabeth Warren

So people can just lie to Congress now and nothing happens? - Business Insider | 8/19/2020

… Elizabeth Warren, and Barack Obama will headline, and Kamala Harris will give her much anticipated acceptance speech. Top health officials delayed emergency FDA approval of blood plasma COVID treatment. The Food and Drug Administration was poised to approve the treatment, which is derived from survivors of COVID-19, but last week Anthony Fauci and the National Institutes of Health director intervened, arguing that the clinical data is not yet strong …

Joe Biden

So people can just lie to Congress now and nothing happens? - Business Insider | 8/19/2020

… all 50 states.” — Rhode Island Democratic Party Chair Joseph M. McNamara , interrupting his state's roll-call endorsement of Joe Biden to tout the local seafood. WHAT'S HAPPENING Alexi Rosenfeld/Getty Images … the National Institutes of Health director intervened, arguing that the clinical data is not yet strong enough to justify the approval. Trump seems to favor Oracle's bid to acquire TikTok's US …

Laura Wood

Clinical Data Has Not Yet Been Published That Would Prove Russia’s COVID-19 Vaccine’s Efficacy | PR Newswire | 8/17/2020

DUBLIN , Aug. 17, ResearchAndMarkets.com published a new article on the COVID-19 vaccine industry “Clinical Data Has Not Yet Been Published That Would Prove Russia’s COVID-19 Vaccine’s Efficacy” Russia has today become the first … focused, comprehensive and tailored research. Media Contact: Research and Markets Laura Wood , Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 …

Louise Chen

Mesoblast scores FDA committee’s backing for cell therapy despite some early worries | FiercePharma | 8/14/2020

… line over its cell therapy, Mesoblast is instead looking at a clear path to market. Despite some pushback over its clinical data and manufacturing process, Mesoblast received a near-unanimous thumbs up Thursday for cell … working with the FDA toward a full approval. Cantor analyst Louise Chen called the vote “clearly good news” for Mesoblast in a note to clients, and shareholders will likely agree. The drugmaker halted trading early …

Jonathan Zalevsky

Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck | PR Newswire | 8/12/2020

Jonathan Zalevsky , Ph.D., Chief Research & Development Officer at Nektar. “The rationale for this clinical study is supported by our promising preclinical data which demonstrated how a personalized cancer vaccine and a T cell proliferator can work synergistically to induce maximal expansion of vaccine-induced T cell clones, provide deep and durable responses and, at the same time, offer specific anti-tumor immunity.” VB10.NEO is designed to specifically activate a …

Alex Azar

Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) | Business Wire | 8/12/2020

… we will have at least one safe, effective vaccine as soon as the end of this year,” said HHS Secretary Alex Azar. “With this latest investment, we will have supported the vaccine candidate developed by … studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna’s proprietary vaccine technology has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical …

James Hayward

Applied DNA Receives Notice of Allowance on Second Patent Protecting Proprietary DNA Transfer System for Large-Scale Cotton Tagging | Business Wire | 8/12/2020

… platform and ensure our ability to deliver supply chain security and authenticity to current and future CertainT customers,” said Dr. James Hayward, president and CEO of Applied DNA. “Despite the downturn in global economic activity … market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s or its partners vaccine candidates will advance further in the preclinical research or clinical trial …

Peter Greenleaf

Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights | Business Wire | 8/11/2020

… significant step towards our goal of delivering the first FDA-approved therapy specifically for people living with lupus nephritis,” commented Peter Greenleaf, President and Chief Executive Officer of Aurinia. “These people suffer from a debilitating … novel and potentially best-in-class calcineurin inhibitor (CNI) with clinical data in over 2,600 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action. By inhibiting calcineurin, voclosporin blocks …

Mark Erlander

Cardiff Oncology Announces Second Quarter 2020 Results and Highlights | PR Newswire | 8/11/2020

Mark Erlander , chief executive officer of Cardiff Oncology. “We announced compelling clinical data demonstrating the safety and efficacy of ovansertib in combination with standard-of-care therapy in KRAS-mutated metastatic colorectal cancer. Additionally, we announced the positive efficacy and safety results of the Phase 1b portion of our trial in relapsed/refractory acute myeloid leukemia and we continue to advance our Phase 2 trial in metastatic castrate-resistant prostate …

J. Joseph Kim

INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update | PR Newswire | 8/10/2020

… its COVID-19 DNA vaccine development program and a mid-year clinical program update for its DNA medicines portfolio. Dr. J. Joseph Kim, INOVIO’s President and Chief Executive Officer, said, “The second quarter further demonstrated … and MERS INO-4800: COVID-19 INOVIO reported positive interim clinical data from the first two cohorts in its Phase 1 clinical trial in the U.S. Specifically: The trial enrolled 40 healthy adult volunteers 18 …

John F. Crowley

Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates Nasdaq:FOLD | Globe Newswire | 8/10/2020

… second quarter ended June 30, 2020. The Company also summarized recent program updates and reiterated its full-year 2020 guidance. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “During the … toxicology work in Pompe disease and progress towards IND Additional preclinical data expected across multiple programs with disclosure of up to two additional IND candidates Manufacturing advancements across portfolio Conference Call and Webcast Amicus Therapeutics …

Joseph Kim

INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update | PR Newswire | 8/10/2020

… COVID-19 DNA vaccine development program and a mid-year clinical program update for its DNA medicines portfolio. Dr. J. Joseph Kim, INOVIO’s President and Chief Executive Officer, said, “The second quarter further demonstrated the … and MERS INO-4800: COVID-19 INOVIO reported positive interim clinical data from the first two cohorts in its Phase 1 clinical trial in the U.S. Specifically: The trial enrolled 40 healthy adult volunteers 18 …

John P. Butler

Akebia Reports Second Quarter 2020 Financial Results | PR Newswire | 8/10/2020

… in adult patients on dialysis, and topped off the quarter with the first regulatory approval of vadadustat in Japan ,” said John P. Butler , President and Chief Executive Officer of Akebia Therapeutics. “The next chapter of … vendors and customers operate; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials, including PRO 2 TECT; the risk that clinical trials may …

Paul Stoffels

Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies | PR Newswire | 7/30/2020

clinical data because they show our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose. The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a Phase 1/2a trial in July with the intention to move into a Phase 3 trial in September,” said Paul Stoffels , M.D., Vice Chairman of the Executive Committee and …

John Reed

Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation | PR Newswire | 7/29/2020

… interactive Multichannel News Release here: https://www.multivu.com/players/English/8751951-sanofi-earnings-results-q2-2020/ Paul Hudson, Chief Executive Officer, Sanofi John Reed, M.D., Ph.D., Executive Vice President, Global Head of Research & Development Jean-Baptiste de … other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any …

Paul Hudson

Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation | PR Newswire | 7/29/2020

… NASDAQ: SNY ; EURONEXT: SAN) Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8751951-sanofi-earnings-results-q2-2020/ Paul Hudson, Chief Executive Officer, Sanofi John Reed, M.D., Ph.D., Executive Vice President, Global Head … other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any …

Bristol, Connecticut

Protocol Manager - Bristol-Myers Squibb - Eigenbrakel | 6/9/2020

Bristol- The Protocol Manager is responsible to drive the successful and timely execution of global Phase I, II, III and IV clinical research protocols from study startup to final clinical study report within the established budget and timelines. Serves as primary operational contact for the protocol. Coordinates the development of protocol level documents and plans, clinical supply oversight, vendor oversight, enrollment tracking, clinical data review and cleaning, coordination of audit …

New York, New York

Edited Transcript of PTCT earnings conference call or presentation 30-Apr-20 8:30pm GMT | Yahoo News | 5/18/2020

… also want to talk about Analyst Day. It’s becoming increasingly clear that hosting an Analyst Day in mid-June in New York City would not be in the best interest of the health and safety … third quarter. We expect that in combination with our existing clinical data, statistically significant results in 045 would be sufficient for accelerated approval in the U.S. As a reminder, this is a single-site, 40 …

State of New York

Edited Transcript of PTCT earnings conference call or presentation 30-Apr-20 8:30pm GMT | Yahoo News | 5/18/2020

… also want to talk about Analyst Day. It’s becoming increasingly clear that hosting an Analyst Day in mid-June in New York City would not be in the best interest of the health and safety … third quarter. We expect that in combination with our existing clinical data, statistically significant results in 045 would be sufficient for accelerated approval in the U.S. As a reminder, this is a single-site, 40 …

York, Pennsylvania

Edited Transcript of PTCT earnings conference call or presentation 30-Apr-20 8:30pm GMT | Yahoo News | 5/18/2020

… want to talk about Analyst Day. It’s becoming increasingly clear that hosting an Analyst Day in mid-June in New York City would not be in the best interest of the health and safety of … third quarter. We expect that in combination with our existing clinical data, statistically significant results in 045 would be sufficient for accelerated approval in the U.S. As a reminder, this is a single-site, 40 …

Cambridge, Massachusetts

Scientists say they may have found a skinny gene | 5/23/2020

… protein called anaplastic lymphoma kinase, which is involved in cell growth.They pinpointed the variant after looking at DNA samples and clinical data of more than 47,000 healthy people in Estonia between the ages of 20 … director of the metabolic diseases unit at the University of Cambridge, said the research was “not definitive” but “very interesting.”O’Rahilly, who wasn’t involved in the study, added that “it certainly increases interest in ALK7 …

State of Texas

Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions | Globe Newswire | 6/13/2020

THE WOODLANDS, Texas, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for Zynquista TM (sotagliflozin) at the virtual 80 th American Diabetes Association (ADA) Scientific Sessions including additional efficacy and safety data patients with type 2 diabetes and moderate and severe renal impairment. Phase 3 CKD-3 Study In the Phase 3, multicenter, randomized, double-blind, placebo-controlled CKD-3 study, sotagliflozin was tested for superiority versus placebo in …

Columbia, South Carolina

Scientists say they may have found a skinny gene | 5/23/2020

clinical data of more than 47,000 healthy people in Estonia between the ages of 20 and 44.”The Estonia biobank is very unique in its detail,” said senior author Josef Penninger, a professor in the department of medical genetics and the director of the Life Sciences Institute at the University of British Columbia.”We looked at the genetic maps of people with a BMI below 18 and compared them with …

Columbia, Missouri

Scientists say they may have found a skinny gene | 5/23/2020

clinical data of more than 47,000 healthy people in Estonia between the ages of 20 and 44.”The Estonia biobank is very unique in its detail,” said senior author Josef Penninger, a professor in the department of medical genetics and the director of the Life Sciences Institute at the University of British Columbia.”We looked at the genetic maps of people with a BMI below 18 and compared them with …

State of California

Lucile Packard Children’s Hospital Stanford Named as a Top 10 Children’s Hospital in the Nation by ‘U.S. News & World Report’ | PR Newswire | 6/16/2020

… 2021 Best Children’s Hospitals survey, published today . The rankings show Packard Children’s Hospital as the top children’s hospital in Northern California and placed on the Best Children’s Hospitals Honor Roll, a designation awarded to pediatric … U.S. News & World Report Best Children’s Hospitals rankings rely on clinical data and on an annual survey of pediatric specialists. The rankings methodology factors in patient outcomes, such as mortality and infection rates, as well …

State of New Jersey

Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer | PR Newswire | 6/25/2020

New Jersey . The phase 2 trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte’s anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in patients with unresectable locally advanced or metastatic TNBC. “We are very excited to evaluate pelareorep in TNBC, as prior clinical data show it has the potential to address a pressing unmet need in this challenging indication,” said principal investigator Mridula George , M.D., Medical …

State of Florida

Fresh Wave Prompts Curbs; India Has Million Cases: Virus Update | Yahoo News | 7/17/2020

… weeks. Earlier, India became the third country to record more than a million cases while Brazil surpassed two million infections. Florida and Texas reported a record numbers of deaths, while Dr. Anthony Fauci said many … Pre-Clinical Trials (2:40 p.m. HK) Marinomed Biotech said pre-clinical data show its Carragelose product has the “potential to reduce the risk of an infection with SARS-CoV-2 and may also treat COVID …

State of Washington

NeoTract Designates Dr. Robert Valenzuela as UroLift® Center of Excellence | PRWeb | 7/29/2020

… Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Robert Valenzuela M.D., Washington Heights Urology in New York, NY, has been designated as a UroLift® Center of … the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and …

State of Pennsylvania

After saving his own life with a repurposed drug, this professor now leads a review of every one being tried against Covid-19 | MSN | 6/29/2020

… Baggott/Channel Street Media Dr. David Fajgenbaum, who leads the Center for Cytokine Storm Treatment & Laboratory at the University of Pennsylvania, is on the front line of aiding doctors fighting the novel coronavirus. Then he … effective drug impotent. But with massive amounts of patients, the clinical data was bearing out a few noticeable themes, he said. First, the Covid-19 patients with more severe cytokine storms were more likely to …

Chicago, Illinois

Clinical Features and Rules of Chinese Herbal Medicine in Diabetic Peripheral Neuropathy Patients | 7/17/2020

… peripheral neuropathy (DPN) and employ data mining technology to explore the rules of Chinese herbal medicine (CHM) therapy. Methods . The clinical data of 216 patients with DPN and qi-yin deficiency syndrome were obtained, and … analyses were performed using SPSS 23.0 statistical software (SPSS Inc., Chicago, IL, USA). Measurement data with a normal distribution are expressed as the mean ± standard deviation (SD), and the squared deviation method was used for …

Boston, Massachusetts

TA Associates and Francisco Partners Announce Significant Growth Investment in Edifecs | Business & Finance | heraldchronicle.com | Business Wire | 7/28/2020

TA Associates and Francisco Partners Announce Significant Growth Investment in Edifecs Jul 28, 2020 Save BOSTON & SAN FRANCISCO & BELLEVUE, Wash.–(BUSINESS WIRE)–Jul 28, 2020– TA Associates, a leading global growth private equity firm, and … by optimizing the secure exchange and processing of administrative and clinical data, reducing the cost of meeting various regulations and automating workflows involved in multiple core processes within the healthcare ecosystem. Edifecs is a frontrunner …

State of Massachusetts

Enterome Completes €46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline | PR Newswire | 6/25/2020

… and Adrenal Tumors during mid-2020 News provided by Jun 25, 2020, 03:00 ET Share this article PARIS and CAMBRIDGE, Massachusetts , June 25, 2020 /PRNewswire/ – ENTEROME SA , a clinical-stage biopharmaceutical company leveraging its unique … its global partner Takeda Pharma to deliver proof-of-concept clinical data with EB8018 (sibofimloc/TAK-018), an oral FimH blocker for the treatment of Crohn’s disease. “Takeda’s participation in this fundraising round builds on …

State of Michigan

Clinical Features and Rules of Chinese Herbal Medicine in Diabetic Peripheral Neuropathy Patients | 7/17/2020

… peripheral neuropathy (DPN) and employ data mining technology to explore the rules of Chinese herbal medicine (CHM) therapy. Methods . The clinical data of 216 patients with DPN and qi-yin deficiency syndrome were obtained, and … wallichii and Moutan bark were highly related to a decreased Michigan Diabetic Neuropathy Score. Conclusion . HbA1c and HCY are related risk factors for DPN. Numbness is a typical syndrome characteristic. Astragalus membranaceus is a monarch …

State of Minnesota

Monitoring and Evaluation Officer US Non-profit Careers - Center for Victims of Torture (CVT) | 6/22/2020

… Minnesota, and we have US offices in Atlanta and DC, as well as offices in Africa and the Middle East. Job Summary: The Monitoring & Evaluation (M&E) Officer is responsible for the entry, analysis, and reporting of program data, including confidential clinical data. The Monitoring & Evaluation Officer will implement and maintain data collection systems, monitor the integrity of collected data, and provide oversight for the data collection process generally; contribute …

Los Angeles, California

Los Angeles County Department of Health Services Partners with LANES to Populate Empaneled Life Management Platform | PR Newswire | 7/29/2020

LOS ANGELES , July 28, The Los Angeles Network for Enhanced Services ( LANES ) announced today that its repository of secure health information exchange (HIE) data will inform the Los Angeles County Department of Health Services ‘ (DHS … the ELM reminder.” LANES provides DHS with near real-time clinical data such as hospital admissions and discharges, allergies, medications, lab results, diagnostic results and procedures from 29 non-DHS acute care hospitals and more …

Charlotte, North Carolina

Atrium Health’s Levine Children’s Hospital Named a “Best Children’s Hospital” for 13th Consecutive Year | PR Newswire | 6/23/2020

CHARLOTTE, N.C. , June 23, For the 13 th consecutive year, Atrium Health’s Levine Children’s Hospital has been recognized as one of the best places to care for children in the nation by U.S. News & World … information on U.S. pediatric hospitals. They are compiled from key clinical data from nearly 200 medical centers through a detailed survey that looks at measures such as reputation, patient and family satisfaction, patient safety and …

State of Kentucky

The Latest: India Reports Record 40,425 New Virus Cases | U.S. News & World Report | 7/20/2020

… with whether to require teachers and students to wear face masks — Workers turn into amateur sleuths to track virus cases — Kentucky announces single-day high of new coronavirus cases, governor says it should be a … development, but until Monday only one had produced Phase 1 clinical data. Also Monday, WHO director-general Tedros Adhanom Ghebreyesus expressed concerns about the COVID-19’s impact on indigenous peoples, particularly in the Americas …

State of Maryland

Effects of TPH2 gene variation and childhood trauma on the clinical and circuit-level phenotype of functional movement disorders | BMJ | 7/20/2020

… Health , Bethesda , MD , USA 2 Office of Biostatistics , National Institute on Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA , Bethesda , Maryland , USA 3 Department of Neurology , Stony Brook University Renaissance School of … versus homozygous and heterozygous for the variant allele). Demographic and clinical data were tested for normal distribution using the Shapiro-Wilk test. Prior to each analysis, we tested the differences between genotype groups using Fisher’s …

Miami, Florida

258+ healthcare revenue cycle companies to know | 2020 | Becker’s Hospital Review | 6/19/2020

… rating and companies are listed in alphabetical order. 4medica (Marina del Rey, Calif.). 4medica was founded as a cloud-based clinical data exchange provider with the company’s flagship clinical integration platform, iEHR, addressing connectivity needs … organization claims Medicare uncollectible receivables on their cost report. CareCloud (Miami). CareCloud provides cloud-based revenue cycle management, practice management, EHR and patient experience management solutions for high-performance medical groups. CareCloud helps clients increase …

State of Arizona

Head to Head Comparison: Solbright Group (OTCMKTS:SBRT) versus OmniComm Systems (OTCMKTS:OMCM) | 6/12/2020

… LLC, doing business as Iota, provides IoT connectivity solutions. The company was incorporated in 2013 and is based in Phoenix, Arizona. OmniComm Systems Company Profile OmniComm Systems, Inc., a healthcare technology company, provides Web-based … that comprises a set of tools for collecting and managing clinical data, including EDC for real-time entry and double data entry (DDE) for entry from paper originals; and Promasys, a clinical trial data management …

Salt Lake City, Utah

258+ healthcare revenue cycle companies to know | 2020 | Becker’s Hospital Review | 6/19/2020

… rating and companies are listed in alphabetical order. 4medica (Marina del Rey, Calif.). 4medica was founded as a cloud-based clinical data exchange provider with the company’s flagship clinical integration platform, iEHR, addressing connectivity needs … healthcare industry, connecting providers, health plans and technology partners. Aviacode (Salt Lake City). Aviacode provides a medical coding solutions platform aimed at solving coding problems, creating efficiencies and improving revenue and cash flow. The company …